28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Although the presence of abnormal levels of amyloid-β (Aβ) is associated with higher rates of progression to clinically classified mild cognitive impairment or dementia, little research has evaluated potentially modifiable moderators of Aβ-related cognitive decline, such as anxiety and depressive symptoms. 5 key findings →
Design: cohort study Participants: 333 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have largely remained elusive, until recently. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease. 1 key finding →
Design: open-label trial Participants: 175 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, patients with Alzheimer dementia who took brexpiprazole, 2 or 3 mg, showed a statistically significant improvement vs placebo in agitation over 12 weeks. 3 key findings →
Participants: 228 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The mean (SD) age in the CA group was 72.2(7.5) years (range, 60-80 years), and in the placebo group it was 71.7 (7.4) years(range, 60-80 years). 3 key findings →
Participants: 261 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
All treatment groups showed improvement in measures of psychosis without significant differences between them when planned comparisons were performed. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Treatment also increased REM sleep duration and reduced ADAS-cog scores. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) often represents an early form of Alzheimer disease (AD). 2 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Overall, 318 patients with AD completed BPST with an improvement of 5.6 points on the total Cohen-Mansfield Agitation Inventory (CMAI; mean [SD], 63.3 [16.0] to 57.7 [18.4], t = 4.8, df = 317, p 95% of patients. 2 key findings →
Design: randomized controlled trial Participants: 318 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
After 3 months, IG improved gait speed (p = 0.016), implying a statistically significant difference between groups in favour of IG (p = 0.003). 3 key findings →
Design: randomized controlled trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Observational studies support the use of NSAIDs for prevention of AD, but RCT do not. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Older adults with diabetes and dementia are at increased risk for hypoglycemia and other adverse events associated with tight glycemic control and are unlikely to experience long-term benefits. 4 key findings →
Design: cohort study Participants: 15,880 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The preponderance of epidemiologic and tissue compositional studies supports a protective effect of omega-3 EFA intake, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in mood disorders. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Future confirmation in a larger study is needed to fully demonstrate rosiglitazone's therapeutic potential. 3 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Based on the hypothesis of glutamate-induced neurotoxicity (excitotoxicity) in cerebral ischemia, this study examined the efficacy and tolerability of memantine, an uncompetitive N-methyl-D-aspartate antagonist, in the treatment of mild to moderate vascular dementia. 4 key findings →
Participants: 321 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). 4 key findings →
Design: randomized controlled trial Participants: 579 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The long-term efficacy and safety of donepezil (up to 10 mg/day) was evaluated in a multicentre, non-randomised, open-label extension study of 133 patients with mild to moderate Alzheimer's disease (AD) who had completed a previous 14-week double-blind, placebo-controlled trial of donepezil. 4 key findings →
Design: open-label trial Participants: 133 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). 4 key findings →
Participants: 188 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients with Alzheimer dementia from the Swedish Dementia Registry starting on ChEIs within 3 months of the dementia diagnosis were included and compared to nontreated patients with Alzheimer dementia. 4 key findings →
Participants: 11,652 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings illuminate the potential benefits of ChEI treatment in DLB patients. 4 key findings →
Design: cohort Participants: 1,095 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. 4 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
10 of the 3,071 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →